Chang Susie, Perry Julian D, Kosmorsky Gregory S, Braun William E
Cole Eye Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Ophthalmic Plast Reconstr Surg. 2007 May-Jun;23(3):225-6. doi: 10.1097/IOP.0b013e3180500d57.
We report a patient with dysthyroid optic neuropathy refractory to steroids and orbital decompression treated with rapamycin, a fibroblast and T cell inhibitor. Symptoms, visual acuity, color plate testing, and visual fields improved. Aside from hypercholesterolemia, no complication related to this therapy was observed. By addressing the pathogenesis of thyroid eye disease, rapamycin may represent an alternative when standard treatments fail. Further investigation of rapamycin for treatment of dysthyroid orbitopathy is warranted.
我们报告了一名患有甲状腺功能障碍性视神经病变的患者，该患者对类固醇和眼眶减压治疗无效，随后接受了雷帕霉素治疗，雷帕霉素是一种成纤维细胞和T细胞抑制剂。症状、视力、色板测试和视野均有改善。除高胆固醇血症外，未观察到与该治疗相关的并发症。通过解决甲状腺眼病的发病机制，当标准治疗失败时，雷帕霉素可能是一种替代方案。有必要对雷帕霉素治疗甲状腺功能障碍性眼眶病进行进一步研究。
